Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...
Tectonic Therapeutic (TECX) announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, ...
Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...
Shares of Tectonic Therapeutic (NASDAQ:TECX) added ~40% in the premarket on Thursday after the cardiac medicines developer ...
Tectonic Therapeutic said the findings support the design and population for Phase 2 APEX trial, which will test TX45 in ...
In a report released yesterday, Tiago Fauth from Wells Fargo reiterated a Buy rating on Tectonic Therapeutic (TECX – Research Report), with a ...
Shares of Tectonic plummeted 41% Tuesday following news that a similar drug developed by Eli Lilly (NYSE:LLY) for chronic kidney disease was terminated due to a lack of foreseeable clinical benefit.
The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an overlapping patient population.
Tectonic Therapeutic TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback